Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

And its investments in AI could, eventually, lead to important monetization opportunities even beyond advertising, perhaps ...

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the ...

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

Recursion claims that its artificial-intelligence-backed drug discovery platform gets smarter each time it pinpoints a new drug candidate—which is why, even with several of those candidates already in ...

For a biotech like Recursion Pharmaceuticals (RXRX 2.50%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...